• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by NanoVibronix Inc.

    5/19/25 10:29:36 AM ET
    $NAOV
    Industrial Specialties
    Health Care
    Get the next $NAOV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    NANOVIBRONIX INC.

    (Name of Issuer)


    COMMON STOCK, $0.001 PAR VALUE PER SHARE

    (Title of Class of Securities)


    63008J702

    (CUSIP Number)


    05/16/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    63008J702


    1Names of Reporting Persons

    Alpha Capital Anstalt
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    LIECHTENSTEIN
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    82,471.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    82,471.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    82,471.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    CO

    Comment for Type of Reporting Person:  Note to 5, 7, 9 and 11: Based on 825,533 shares outstanding as of April 29, 2025 as reported on Form S-1/A filed with the Securities and Exchange Commission on May 14, 2025. Note to 10: The aggregate amount in Row 9 represents the maximum amount of shares that Alpha Capital Anstalt can beneficially control under a contractually stipulated 9.99% ownership restriction. The full conversion and/or exercise of Alpha Capital Anstalt's securities would exceed this restriction.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    NANOVIBRONIX INC.
    (b)Address of issuer's principal executive offices:

    969 Pruitt Ave,, Tyler, TX, 77569
    Item 2. 
    (a)Name of person filing:

    Alpha Capital Anstalt
    (b)Address or principal business office or, if none, residence:

    Altenbach 8, FL-9490 Vaduz, Liechtenstein
    (c)Citizenship:

    Liechtenstein
    (d)Title of class of securities:

    COMMON STOCK, $0.001 PAR VALUE PER SHARE
    (e)CUSIP No.:

    63008J702
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    82,471.00
    (b)Percent of class:

    9.99%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    82,471.00

     (ii) Shared power to vote or to direct the vote:

    0 Shares

     (iii) Sole power to dispose or to direct the disposition of:

    82,471.00

     (iv) Shared power to dispose or to direct the disposition of:

    0 Shares

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Alpha Capital Anstalt
     
    Signature:/s/ Konrad Ackermann
    Name/Title:Konrad Ackermann/Director
    Date:05/19/2025
    Get the next $NAOV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NAOV

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NAOV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • NanoVibronix Announces Closing of $10 Million Public Offering of Preferred Stock and Warrants

      NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the closing of its previously announced underwritten public offering of 400,000 shares of the Company's Series G Convertible Preferred Stock ("Preferred Stock"), with a par value $0.001 per share and a stated value equal to $25, and Warrants to purchase up to 4,901,982 shares of common stock, par value $0.001 per share (the "Common Stock") of the Company at an exercise price of $2.04 per share (the "Warrants"). The combined public offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00. The Warrants have

      5/16/25 4:30:00 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Announces Pricing of $10 Million Public Offering of Preferred Stock and Warrants

      NanoVibronix, Inc. (NASDAQ:NAOV) ("NanoVibronix" or the "Company"), a medical technology company specializing in therapeutic devices, today announced the pricing of an underwritten public offering of approximately 400,000 shares of the Company's Series G Convertible Preferred Stock ("Preferred Stock"), par value $0.001 per share and Warrants to purchase up to 4,901,961 shares of common stock, par value $0.001 per share (the "Common Stock") of the Company at an exercise price of $2.04 per share (the "Warrants"). The combined public offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00. The closing of the public offering is expected to occur on or abo

      5/15/25 9:00:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Announces Results from UroShield™ Case Series

      UroShield Demonstrates Significant Reductions in CAUTIs, Catheter Blockages and Hospital Visits NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical technology company specializing in therapeutic devices, today announced findings from a recent retrospective case series evaluating the clinical impact and patient experience of the UroShield™ system. The case series, conducted between September 2023 and January 2025 by researchers at University Hospitals Coventry and Warwickshire Partnership NHS, assessed a small group of patients who used the UroShield device for durations ranging from 12 weeks to 17 months. The series reviewed pre- and post-treatment data on catheter-associated urin

      5/12/25 8:50:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by NanoVibronix Inc.

      SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

      11/14/24 5:17:34 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G filed by NanoVibronix Inc.

      SC 13G - NanoVibronix, Inc. (0001326706) (Subject)

      2/14/24 3:45:41 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - NanoVibronix, Inc. (0001326706) (Subject)

      2/16/21 3:49:24 PM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Financials

    Live finance-specific insights

    See more
    • NanoVibronix Announces Distribution of Series F Preferred Stock to Holders of its Common Stock

      NanoVibronix, Inc. (NASDAQ:NAOV) ("Nano" or the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series F Preferred Stock, par value $0.001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on October 14, 2022. The shares of Series F Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on October 17, 2022. The outstanding shares of Series F Preferred Stock will vote together with the outstanding sh

      9/14/22 9:25:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $NAOV
    SEC Filings

    See more
    • SEC Form 4 filed by Chief Executive Officer Murphy Brian M

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/3/25 4:05:16 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Director Mika Thomas

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/2/25 9:26:30 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 4 filed by Chief Financial Officer Brown Stephen Russell

      4 - NanoVibronix, Inc. (0001326706) (Issuer)

      1/2/25 9:25:07 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form 10-Q filed by NanoVibronix Inc.

      10-Q - NanoVibronix, Inc. (0001326706) (Filer)

      5/20/25 5:19:27 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • SEC Form SCHEDULE 13G filed by NanoVibronix Inc.

      SCHEDULE 13G - NanoVibronix, Inc. (0001326706) (Subject)

      5/19/25 10:29:36 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

      8-K - NanoVibronix, Inc. (0001326706) (Filer)

      5/16/25 4:05:31 PM ET
      $NAOV
      Industrial Specialties
      Health Care

    $NAOV
    Leadership Updates

    Live Leadership Updates

    See more
    • NanoVibronix Announces Results of Annual Meeting of Stockholders Held Today

      NanoVibronix, Inc. (NASDAQ:NAOV) (the "Company"), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, announced that the Company's 2022 annual meeting of stockholders (the "Annual Meeting") was held today virtually and broadcast live at www.virtualshareholdermeeting.com/NAOV2022. The following resolutions submitted for stockholder approval were adopted: Election of the eight director nominees (Aurora Cassirer, Christopher Fashek, Michael Ferguson, Martin Goldstein, M.D., Harold Jacob, M.D., Thomas Mika, Brian Murphy, and Maria Schroeder) to serve on the Company's board of directors (the "Board"), for a term of on

      12/15/22 4:05:00 PM ET
      $NAOV
      Industrial Specialties
      Health Care
    • NanoVibronix Reports First Quarter 2022 Financial Results

      Expanded Distribution, Entry into New Geographic Markets and Regulatory Approvals Advancing Efforts Towards Full Commercialization NanoVibronix, Inc., (NASDAQ:NAOV), a medical device company utilizing the Company's proprietary and patented low intensity surface acoustic wave (SAW) technology, today reported its financial results for the quarter ended March 31, 2022. First Quarter 2022 Financial and Recent Business Highlights Revenue of $272,000, an increase of 164% compared to the prior year period Significant backlog of orders to be filled in Q2 Supply chain challenges are expected to abate moving into the second half of 2022 Submitted a 510(k) application to the U.S. Food and Dr

      5/17/22 8:30:00 AM ET
      $NAOV
      Industrial Specialties
      Health Care
    • Cerro de Pasco Announces MCTO and New Chief Financial Officer

      MONTREAL, April 29, 2022 /CNW Telbec/ - Cerro de Pasco Resources Inc. (CSE:CDPR) (Frankfurt: N8HP) ("CDPR" or the "Company") announces that it has applied to the Autorité des marchés financiers (Québec) (the "AMF"), as principal regulator of the Company, and expects to be granted a management cease trade order (the "MCTO") on May 2, 2022, pursuant to Policy Statement 12-203 Respecting Management Cease Trade Orders ("PS 12-203"). Under the MCTO, the Company's Chief Executive Officer (CEO), Chief Financial Officer (CFO) and directors may not trade in securities of the Company until such time as the Company files its audited consolidated financial statements, its management's discussion and ana

      4/29/22 3:28:00 PM ET
      $GMBL
      $NAOV
      Services-Misc. Amusement & Recreation
      Consumer Discretionary
      Industrial Specialties
      Health Care